Taro Pharmaceutical Industries Ltd. (TARO)
NYSE: TARO · IEX Real-Time Price · USD
42.20
-0.03 (-0.07%)
Apr 24, 2024, 4:00 PM EDT - Market closed
TARO Balance Sheet
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| Year | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 - 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 154.5 | 251.13 | 605.18 | 513.35 | 567.45 | 576.61 | 600.4 | 576.76 | 481.64 | 209.97 | Upgrade
|
| Short-Term Investments | 695.79 | 569.61 | 418.48 | 595.38 | 481.88 | 846.01 | 786.36 | 651.87 | 438.56 | 422.43 | Upgrade
|
| Cash & Cash Equivalents | 850.29 | 820.75 | 1,024 | 1,109 | 1,049 | 1,423 | 1,387 | 1,229 | 920.2 | 632.4 | Upgrade
|
| Cash Growth | 3.60% | -19.82% | -7.67% | 5.66% | -26.24% | 2.59% | 12.87% | 33.52% | 45.51% | 12.83% | Upgrade
|
| Receivables | 259.47 | 306.7 | 266.89 | 270.79 | 285.31 | 329.42 | 470.2 | 509.34 | 473.34 | 301.16 | Upgrade
|
| Inventory | 226.67 | 210.44 | 180.29 | 153.07 | 148.08 | 144.6 | 141.05 | 138.55 | 120.27 | 117.64 | Upgrade
|
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 1.02 | 1.08 | 0 | 0.07 | Upgrade
|
| Total Current Assets | 1,336 | 1,338 | 1,471 | 1,533 | 1,483 | 1,897 | 1,999 | 1,878 | 1,514 | 1,051 | Upgrade
|
| Property, Plant & Equipment | 190.14 | 199.69 | 205.51 | 209.96 | 206.24 | 193.73 | 180.09 | 159.46 | 153.05 | 151.42 | Upgrade
|
| Long-Term Investments | 404.9 | 435.19 | 557.21 | 459.64 | 304.32 | 225.64 | 70.69 | 115.17 | 30.18 | 0 | Upgrade
|
| Goodwill and Intangibles | 17.23 | 11.82 | 7.19 | 0 | 0 | 0 | 0 | 0 | 0 | 23.89 | Upgrade
|
| Other Long-Term Assets | 186.82 | 191.78 | 166.13 | 139.05 | 142.04 | 117.21 | 39.96 | 35.81 | 40.72 | 57.8 | Upgrade
|
| Total Long-Term Assets | 799.09 | 838.48 | 936.04 | 808.65 | 652.61 | 536.58 | 290.73 | 310.44 | 223.94 | 233.11 | Upgrade
|
| Total Assets | 2,136 | 2,176 | 2,407 | 2,341 | 2,135 | 2,433 | 2,290 | 2,188 | 1,738 | 1,284 | Upgrade
|
| Accounts Payable | 68.49 | 68.23 | 61.17 | 28.86 | 35.06 | 25.7 | 16.39 | 18.85 | 19.48 | 20.8 | Upgrade
|
| Current Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.91 | 11.97 | Upgrade
|
| Other Current Liabilities | 317.06 | 363.89 | 615.14 | 193.87 | 181.76 | 190.06 | 193.44 | 226.61 | 289.61 | 220.54 | Upgrade
|
| Total Current Liabilities | 385.55 | 432.12 | 676.3 | 222.73 | 216.82 | 215.76 | 209.84 | 245.46 | 310.01 | 253.3 | Upgrade
|
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.98 | 5.89 | Upgrade
|
| Other Long-Term Liabilities | 19.11 | 32.8 | 35.12 | 8.76 | 7.38 | 7.06 | 6.11 | 5.43 | 5.38 | 4.59 | Upgrade
|
| Total Long-Term Liabilities | 19.11 | 32.8 | 35.12 | 8.76 | 7.38 | 7.06 | 6.11 | 5.43 | 10.36 | 10.48 | Upgrade
|
| Total Liabilities | 404.66 | 464.92 | 711.42 | 231.49 | 224.2 | 222.81 | 215.95 | 250.89 | 320.36 | 263.78 | Upgrade
|
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.89 | 17.86 | Upgrade
|
| Debt Growth | - | - | - | - | - | - | - | - | -67.04% | -37.54% | Upgrade
|
| Retained Earnings | 2,414 | 2,389 | 2,339 | 2,725 | 2,481 | 2,662 | 2,451 | 1,995 | 1,454 | 969.63 | Upgrade
|
| Comprehensive Income | 0 | -168.97 | -151.62 | -163.04 | -144.11 | -110.29 | -148.13 | -123.03 | -110.97 | -22.9 | Upgrade
|
| Shareholders' Equity | 1,731 | 1,711 | 1,704 | 2,104 | 1,906 | 2,205 | 2,067 | 1,931 | 1,412 | 1,016 | Upgrade
|
| Net Cash / Debt | 850.29 | 820.75 | 1,024 | 1,109 | 1,049 | 1,423 | 1,387 | 1,229 | 914.31 | 614.53 | Upgrade
|
| Net Cash / Debt Growth | 3.60% | -19.82% | -7.67% | 5.66% | -26.24% | 2.59% | 12.87% | 34.38% | 48.78% | 15.54% | Upgrade
|
| Net Cash Per Share | 22.62 | 21.80 | 26.79 | 28.83 | 26.91 | 35.43 | 33.58 | 28.68 | 21.35 | 13.88 | Upgrade
|
| Working Capital | 950.88 | 905.77 | 794.53 | 1,310 | 1,266 | 1,681 | 1,789 | 1,632 | 1,204 | 797.97 | Upgrade
|
| Book Value Per Share | 46.05 | 45.47 | 44.59 | 54.70 | 48.87 | 54.92 | 50.06 | 45.09 | 32.96 | 22.94 | Upgrade
|